Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Otsuka gets exclusive rights to oncolytic virus therapy from Takara Bio; License Agreement Terminated

Executive Summary

Otsuka Pharmaceutical Co. Ltd. licensed exclusive Japanese rights to develop and sell Takara Bio Inc.’s oncolytic virus therapy as a potential cancer treatment.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register